Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 69

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 69
---
  
     (483)%
  
    Loss on extinguishment of debt 
     —  
     (1,303,578) 
     1,303,578) 
     (100)%
  
    Change in fair value of equity securities 
     (112,149) 
     —  
     (112,149) 
     100%
  
    Interest expense 
     (725,684) 
     (1,011,322) 
     285,638  
     (28)%
  
    Interest and other income (expense) 
     116,346  
     (1,423,449) 
     1,539,795  
     (108)%
  
    Total Other Income (Expense) 
     10,958,513  
     (6,786,532) 
     17.745,045  
     (261)%

    NET LOSS 
    $(178,007,489) 
    $(88,425,828) 
     (89,581,661) 
     101%

    For the Years Ended 

    June 30, 
    Increase/(Decrease)

    2025 
    2024 
    $ 
    %

    Net Loss 
    $(178,007,489) 
    $(88,425,828) 
    $(89,581,661) 
     101%
  
    Other Comprehensive Income (Loss) 

     Foreign Currency Translation, net of taxes 
     10,985,688  
     (140,964) 
     11,126,652  
     (7,893)%

    Comprehensive Loss 
    $(167,0021,801) 
    $(88,566,792) 
    $(78,455,009) 
     89%

57

Revenues

We are a pre-revenue, pre-clinical
biotechnology and artificial intelligence driven healthcare technology company. We have never generated revenues and have incurred losses
since inception. We do not anticipate earning any revenues until our therapies or products are approved for marketing and sale.

Operating Expenses

Our operating expenses for the
years ended June 30, 2025 and 2024 were $188,966,002 and $81,639,296, respectively, representing an increase of $107,326,706 or 131%.
The